We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of IRESSA in Relapsed and Refractory Small Cell Lung Cancer

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00298688
First Posted: March 3, 2006
Last Update Posted: June 12, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
AstraZeneca
March 1, 2006
March 3, 2006
June 12, 2008
September 2004
Not Provided
To determine the disease control rate in these patients
Same as current
Complete list of historical versions of study NCT00298688 on ClinicalTrials.gov Archive Site
  • To determine the objective response rate at trail closure in these patients
  • To determine the time to progression-or-death in these patients
  • To determine overall survival in these patients
Same as current
Not Provided
Not Provided
 
A Study of IRESSA in Relapsed and Refractory Small Cell Lung Cancer
Phase II Study of Iressa in Relapsed and Refractory Small Cell Lung Cancer
The purpose of this study is to determine the disease control rate at trial closure and after the first stage of the study in patients with relapsed or refractory SCLC and measurable disease treated with gefitinib
Not Provided
Interventional
Phase 2
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Small Cell Lung Cancer
Drug: Gefitinib
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
56
March 2007
Not Provided

Inclusion Criteria:

  • Provision of written informed consent
  • Histologically confirmed, relapsed or refractory SCLCr
  • Aged 18 or over and a life expectancy of more than 2 months

Exclusion Criteria:

  • Any evidence of clinically active interstitial lung disease
  • Other co-existing malignancies or malignancies diagnosed within the last 5 years, with the exception of basal cell carcinoma or cervical cancer in situ.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Denmark,   United Kingdom
 
 
NCT00298688
1839IL/0559
Not Provided
Not Provided
Not Provided
Not Provided
AstraZeneca
Not Provided
Study Director: AstraZeneca Iressa Medical Science Director, MD AstraZeneca
AstraZeneca
June 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP